JNJ-55308942

• CAT Number: I029837
• CAS Number: 2166558-11-6
• Molecular Formula: C17H12F5N7O
• Molecular Weight: 425.32
• Purity: ≥95%
• Synonyms: [(6S)-1-(5-fluoropyrimidin-2-yl)-6-methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridin-5-yl]-[3-fluoro-2-(trifluoromethyl)pyridin-4-yl]methanone
• InChI: InChI=1S/C17H12F5N7O/c1-8-4-12-11(26-27-29(12)16-24-5-9(18)6-25-16)7-28(8)15(30)10-2-3-23-14(13(10)19)17(20,21)22/h2-3,5-6,8H,4,7H2,1H3/t8-/m0/s1
• InChIKey: LMDWZBQISRTEBH-QMMMGPOBSA-N
• SMILES: CC1CC2=C(CN1C(=O)C3=C(C(=NC=C3)C(F)(F)F)F)N=NN2C4=NC=C(C=N4)F

JNJ-55308942 (Cat No.: I029837) is an orally active, brain-penetrant antagonist of the orexin-1 receptor (OX₁R), a G protein–coupled receptor involved in regulating arousal, reward, and stress responses. By selectively blocking OX₁R, it modulates orexin-mediated signaling without significantly affecting orexin-2 receptor (OX₂R) pathways, reducing the risk of sedation. JNJ-55308942 is primarily investigated for the treatment of anxiety, depression, and substance use disorders. It is used in neuroscience research to explore orexin system modulation as a therapeutic strategy for stress-related and neuropsychiatric conditions.

Reference

[1]. Bhattacharya A, et al. Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia. Neuropsychopharmacology. 2018;43(13):2586-2596.
[Content Brief]

[2]. Chrovian CC, et al. A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate. J Med Chem. 2018;61(1):207-223
[Content Brief]